Search results
Showing 1 to 15 of 51 results for age-related macular degeneration
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)
Evidence-based recommendations on bevacizumab gamma (Lytenava) for treating wet age-related macular degeneration in adults.
Faricimab for treating wet age-related macular degeneration (TA800)
Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.
Brolucizumab for treating wet age-related macular degeneration (TA672)
Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.
Evidence-based recommendations on radiotherapy for age-related macular degeneration. This involves using radiation to destroy the new blood vessels, with the aim of slowing down sight loss.
View recommendations for HTG24Show all sections
Sections for HTG24
Miniature lens system implantation for advanced age-related macular degeneration
Topic prioritisation
Transpupillary thermotherapy for age-related macular degeneration (HTG31)
Evidence-based recommendations on transpupillary thermotherapy for age-related macular degeneration. This involves using a laser to heat and seal up the blood vessels that are causing the problems.
View recommendations for HTG31Show all sections
Sections for HTG31
Miniature lens system implantation for advanced age-related macular degeneration
Awaiting development Reference number: GID-HTG10468 Expected publication date: TBC
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.
In development Reference number: GID-HTE10073 Expected publication date: 15 September 2026
Limited macular translocation for wet age-related macular degeneration (HTG215)
Evidence-based recommendations on limited macular translocation for wet age related macular degeneration. This involves cutting and moving the macula on an a nearby healthier area of the retina.
Miniature lens system implantation for advanced age-related macular degeneration (HTG418)
Evidence-based recommendations on miniature lens system implantation for advanced age-related macular degeneration. This involves implanting an artificial lens system into 1 eye only.
Epiretinal brachytherapy for wet age-related macular degeneration (HTG279)
Evidence-based recommendations on epiretinal brachytherapy for wet age related macular degeneration. This involves using radiation therapy used to destroy the new blood vessels.
View recommendations for HTG279Show all sections
Sections for HTG279